{
    "nctId": "NCT00814125",
    "briefTitle": "ATAC - Endometrial Sub-Protocol",
    "officialTitle": "A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "N/A",
    "enrollmentCount": 285,
    "primaryOutcomeMeasure": "Withdrawl",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients eligible for entry into the main ATAC trial (1033IL/0029)\n* Not received any previous tamoxifen, for whatever reason\n* Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years\n* No previous endometrial ablation\n\nExclusion Criteria:\n\n* Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}